Zentalis Pharmaceuticals EPS Ratio 2011-2025 | ZNTL

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Zentalis Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-4.47	-4.48	-3.72	-4.19	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-3.72	-4.48	-4.21

Quarterly EPS Ratio Zentalis Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.37	-0.37	-0.67	-	-0.56	-1.24	0.14	-	-0.79	-1.85	-1.07	-	-0.96	-1.34	-1.31	-1.11	-0.09	-1.34	-1.24	-1.01	-0.91	-0.78	-2.88	-	-	-	-1.49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
0.14	-2.88	-1.01

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	-0.44	$ 4.85	2.87 %	$ 805 M	Canada
Aclaris Therapeutics ACRS	-1.71	$ 3.21	-1.23 %	$ 248 M	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	-87.4	$ 1.06	-6.64 %	$ 293 K	USA
Ascendis Pharma A/S ASND	-8.28	$ 215.41	-2.27 %	$ 5 B	Danmark
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Alterity Therapeutics Limited ATHE	-0.53	$ 3.15	-3.85 %	$ 7.58 B	Australia
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
BioVie BIVI	-12.1	$ 1.43	-1.39 %	$ 2.11 M	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-0.09	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	42.2	$ 94.02	-0.84 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	3.29	$ 26.2	3.68 %	$ 1.27 B	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	-5.64	$ 9.59	0.31 %	$ 141 M	USA
Can-Fite BioPharma Ltd. CANF	-0.01	$ 0.27	-6.08 %	$ 588 M	Israel
Arena Pharmaceuticals ARNA	-10.1	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	-0.39	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Catalyst Biosciences CBIO	-1.41	$ 13.48	-4.36 %	$ 887 M	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	4.98	$ 549.1	-2.69 %	$ 41.6 B	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.16	$ 2.4	4.34 %	$ 15.1 M	USA
AstraZeneca PLC AZN	0.08	$ 91.04	1.35 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	-1.06	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	75.3	$ 8.87	-1.55 %	$ 1.45 B	Britain
BeiGene, Ltd. BGNE	-0.47	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-13.1	$ 11.23	-2.69 %	$ 726 M	USA
Biogen BIIB	11.2	$ 174.94	0.48 %	$ 25.5 B	USA
Abeona Therapeutics ABEO	-2.53	$ 5.07	-5.5 %	$ 108 M	USA
Celldex Therapeutics CLDX	-2.45	$ 27.11	-1.47 %	$ 1.75 M	USA
ADiTx Therapeutics ADTX	-3.06 K	$ 1.66	-25.84 %	$ 21.9 K	USA
Cellectar Biosciences CLRB	-3.5	$ 3.36	-7.32 %	$ 41.1 M	USA
Bellicum Pharmaceuticals BLCM	-0.81	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-1.42	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA